E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces First Quarter 2023 Financial Results
03 mai 2023 16h01 HE | electroCore, Inc.
Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023, at 4:30 PM EDT ROCKAWAY, N.J., May ...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Annual Aegis Virtual Conference
01 mai 2023 16h01 HE | electroCore, Inc.
ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning
24 avr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
12 avr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan
11 avr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Teijin...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
06 avr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
04 avr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h05 HE | electroCore, Inc.
Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J.,...
National Headache Fo
National Headache Foundation Makes WorkMigraine Program Resources Free to the Public
05 janv. 2023 15h18 HE | National Headache Foundation
Chicago, Illinois, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The National Headache Foundation (NHF) announced it is now making available free to the public its proven WorkMigraine program to help employers...
Axsome Logo.png
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
29 sept. 2022 07h28 HE | Axsome Therapeutics, Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...